George Bigelow

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course
    George E Bigelow
    Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Bayview Campus, Baltimore, MD 21224, USA
    Drug Alcohol Depend 123:57-65. 2012
  2. ncbi Evaluation of an injection depot formulation of buprenorphine: placebo comparison
    Stacey C Sigmon
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Addiction 99:1439-49. 2004
  3. ncbi Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period
    Christopher J Correia
    Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 189:297-306. 2006
  4. ncbi Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification
    Bai Fang X Sobel
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224 6823, USA
    Drug Alcohol Depend 73:11-22. 2004
  5. doi Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects
    Ying Jun Cao
    Division of Clinical Pharmacology, Johns Hopkins University, Baltimore, Maryland 21287 5554, USA
    Pharmacotherapy 28:863-74. 2008
  6. ncbi Modest opioid withdrawal suppression efficacy of oral tramadol in humans
    Michelle R Lofwall
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Psychopharmacology (Berl) 194:381-93. 2007
  7. doi Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation
    Ryan K Lanier
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Psychopharmacology (Berl) 198:149-58. 2008
  8. ncbi Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers
    Eric C Donny
    Behavioral Pharmacology Research Unit, Department of Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, USA
    Addiction 100:1496-509. 2005
  9. ncbi Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine
    Eric C Strain
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 159:161-6. 2002
  10. pmc Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone
    James Rosado
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Drug Alcohol Depend 90:261-9. 2007

Research Grants

  1. HUMAN BEHAVIORAL PHARMACOLOGY OF SUBSTANCE ABUSE
    George Bigelow; Fiscal Year: 2007
  2. PHARMACOLOGICAL MODULATION OF COCAINE EFFECTS
    George Bigelow; Fiscal Year: 2002
  3. HUMAN BEHAVIORAL PHARMACOLOGY OF DRUG ABUSE
    George Bigelow; Fiscal Year: 2002
  4. PHARMACOLOGICAL MODULATION OF COCAINE EFFECTS
    George Bigelow; Fiscal Year: 1993
  5. PHARMACOLOGICAL MODULATION OF COCAINE EFFECTS
    George Bigelow; Fiscal Year: 1991

Detail Information

Publications38

  1. pmc Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course
    George E Bigelow
    Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Bayview Campus, Baltimore, MD 21224, USA
    Drug Alcohol Depend 123:57-65. 2012
    ..This study evaluated the effects of extended-release injectable naltrexone (XR-NTX), targeted for a one-month duration of action, in blocking opioid agonist challenge effects in humans...
  2. ncbi Evaluation of an injection depot formulation of buprenorphine: placebo comparison
    Stacey C Sigmon
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Addiction 99:1439-49. 2004
    ..The present study examined the efficacy of depot buprenorphine in suppressing the opioid withdrawal syndrome and in attenuating the effects of exogenous opioid challenge...
  3. ncbi Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period
    Christopher J Correia
    Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 189:297-306. 2006
    ..Buprenorphine has a long duration of action that allows less than daily dosing for opioid dependence, but pharmacologic characterization of buprenorphine's duration of effects over multiple days is incomplete...
  4. ncbi Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification
    Bai Fang X Sobel
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224 6823, USA
    Drug Alcohol Depend 73:11-22. 2004
    ..Results from the present study suggest that depot buprenorphine offers significant promise for enhancing the delivery of effective opioid agonist treatment while minimizing risk for abuse of the medication...
  5. doi Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects
    Ying Jun Cao
    Division of Clinical Pharmacology, Johns Hopkins University, Baltimore, Maryland 21287 5554, USA
    Pharmacotherapy 28:863-74. 2008
    ..To compare steady-state pharmacokinetics and pharmacodynamics of methadone enantiomers when coadministered with fosamprenavir 700 mg-ritonavir 100 mg twice/day...
  6. ncbi Modest opioid withdrawal suppression efficacy of oral tramadol in humans
    Michelle R Lofwall
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Psychopharmacology (Berl) 194:381-93. 2007
    ..Tramadol is in an unscheduled atypical analgesic with low rates of diversion and abuse and mixed pharmacologic actions, including modest opioid agonist activity...
  7. doi Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation
    Ryan K Lanier
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Psychopharmacology (Berl) 198:149-58. 2008
    ..Buprenorphine is one effective detoxification treatment, however, consensus regarding effective detoxification procedures is lacking...
  8. ncbi Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers
    Eric C Donny
    Behavioral Pharmacology Research Unit, Department of Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, USA
    Addiction 100:1496-509. 2005
    ..This greater efficacy may result from greater cross-tolerance to the reinforcing effects of heroin...
  9. ncbi Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine
    Eric C Strain
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 159:161-6. 2002
    ..Naloxone has been combined with buprenorphine to decrease the parenteral abuse potential of buprenorphine. This addition of naloxone may also confer further opioid blockade efficacy...
  10. pmc Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone
    James Rosado
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Drug Alcohol Depend 90:261-9. 2007
    ..Acute doses of buprenorphine can precipitate withdrawal in opioid dependent persons. The likelihood of this withdrawal increases as a function of the level of physical dependence...
  11. ncbi Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence
    Lisa A Marsch
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Exp Clin Psychopharmacol 13:293-302. 2005
    ..We did not find any factors that would strongly guide selection of one medication over others...
  12. ncbi An injection depot formulation of buprenorphine: extended bio-delivery and effects
    Stacey C Sigmon
    Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, MD
    Addiction 101:420-32. 2006
    ..This report provides a characterization of the bio-delivery of this injectable depot in humans and of the relationship of drug blood levels to pharmacodynamic indices...
  13. ncbi Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans
    C Patrick Carroll
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Exp Clin Psychopharmacol 14:109-20. 2006
    ..In contrast, tramadol's pattern of effects was more similar to that of hydromorphone and suggestive of mild opioid-agonist effects (withdrawal suppression), though not to a statistically significant degree...
  14. pmc Effects of repeated tramadol and morphine administration on psychomotor and cognitive performance in opioid-dependent volunteers
    Miriam Z Mintzer
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Drug Alcohol Depend 111:265-8. 2010
    ..These findings suggest that tramadol is generally a safe medication with respect to cognitive and psychomotor measures and support tramadol's further evaluation as an opioid-dependence treatment...
  15. pmc Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone
    David Andrew Tompkins
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Psychopharmacology (Berl) 210:471-80. 2010
    ..Prescription opioid abuse has risen dramatically in the United States as clinicians have increased opioid prescribing for alleviation of both acute and chronic pain. Opioid analgesics with decreased risk for abuse are needed...
  16. pmc Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument
    D Andrew Tompkins
    Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, Behavioral Pharmacology Research Unit, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Drug Alcohol Depend 105:154-9. 2009
    ..Though commonly used in clinical practice, it has not been systematically validated. The present study validated the COWS in comparison to the validated Clinical Institute Narcotic Assessment (CINA) scale...
  17. pmc Contingency management in cocaine abusers: a dose-effect comparison of goods-based versus cash-based incentives
    Ryan Vandrey
    Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Exp Clin Psychopharmacol 15:338-43. 2007
    ....
  18. ncbi Evaluation of a transdermal buprenorphine formulation in opioid detoxification
    Ryan K Lanier
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA
    Addiction 102:1648-56. 2007
    ..This study evaluated the safety and biodelivery (blood levels) of this transdermal buprenorphine formulation (i.e. buprenorphine patch), and its apparent efficacy in suppressing the opioid withdrawal syndrome...
  19. ncbi Characteristics of older opioid maintenance patients
    Michelle R Lofwall
    Johns Hopkins University School of Medicine Behavioral Pharmacology Research Unit and Addiction Treatment Services, Baltimore, MD 21224, USA
    J Subst Abuse Treat 28:265-72. 2005
    ..Low rates of positive urine opioid tests occurred for both older and younger patients without age-specific services...
  20. ncbi High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans
    Eric C Donny
    Behavioral Pharmacology Research Unit, Department of Psychiatry, Johns Hopkins School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 161:202-12. 2002
    ..The efficacy of methadone for treating heroin dependence derives, in part, from suppression of opiate withdrawal and attenuation of the effects of heroin...
  21. ncbi A reinforcement-based therapeutic workplace for the treatment of drug abuse: three-year abstinence outcomes
    Kenneth Silverman
    Center for Learning and Health, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Exp Clin Psychopharmacol 10:228-40. 2002
    ..05) abstinence on the basis of monthly urine samples collected until 3 years after intake. The Therapeutic Workplace can be an effective long-term treatment of cocaine and heroin addiction in poor and chronically unemployed young mothers...
  22. ncbi Choosing to take cocaine in the human laboratory: effects of cocaine dose, inter-choice interval, and magnitude of alternative reinforcement
    Eric C Donny
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Drug Alcohol Depend 69:289-301. 2003
    ..Inter-choice interval did not affect cocaine choices. These results illustrate the persistence of cocaine self-administration once cocaine-taking has been initiated...
  23. ncbi Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans
    Sharon L Walsh
    Behavioral Pharmacology Research Unit, Department of Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD 21224, USA
    Addiction 98:427-39. 2003
    ..To examine the efficacy of lofexidine, an alpha2 adrenergic agonist, to suppress opioid withdrawal symptoms in opioid-dependent humans under in-patient laboratory conditions by using a naloxone challenge procedure...
  24. ncbi Principles of initial experimental drug abuse liability assessment in humans
    Roland R Griffiths
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Drug Alcohol Depend 70:S41-54. 2003
    ..g. behavioral performance, observer-rated assessments, physiological measures)...
  25. ncbi Transdermal selegiline and intravenous cocaine: safety and interactions
    Elisabeth J Houtsmuller
    Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Bayview Medical Center, 5510 Nathan Shock Drive, Baltimore, MD 21224 6823, USA
    Psychopharmacology (Berl) 172:31-40. 2004
    ..Selegiline, a selective monoamine oxidase B inhibitor, indirectly modulates dopamine levels, and research suggests selegiline may modify subjective effects of cocaine...
  26. ncbi Assessing the initiation of cocaine self-administration in humans during abstinence: effects of dose, alternative reinforcement, and priming
    Eric C Donny
    Behavioral Pharmacology Research Unit, Johns Hopkins School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 172:316-23. 2004
    ..One potential trigger of cocaine-taking is exposure to cocaine (i.e. priming)...
  27. ncbi A randomized trial of long-term reinforcement of cocaine abstinence in methadone-maintained patients who inject drugs
    Kenneth Silverman
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    J Consult Clin Psychol 72:839-54. 2004
    ..Therefore, voucher-based reinforcement of cocaine abstinence in methadone patients can be a highly effective maintenance intervention...
  28. ncbi Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects
    Craig W Hendrix
    Johns Hopkins University School of Medicine, Baltimore, MD 21287 5554, USA
    Pharmacotherapy 24:1110-21. 2004
    ..To investigate the steady-state pharmacokinetics of methadone enantiomers when coadministered with amprenavir...
  29. ncbi Safety and efficacy of L-tryptophan and behavioral incentives for treatment of cocaine dependence: a randomized clinical trial
    Hendree E Jones
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Am J Addict 13:421-37. 2004
    ..This study also showed that contingent vouchers were effective in the novel experimental model of relapse prevention...
  30. pmc Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers
    Angela N Duke
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 211:303-12. 2010
    ..However, the addition of naloxone may not limit abuse potential of this medication when taken by individuals without opioid physical dependence...
  31. ncbi Relative bioavailability of different buprenorphine formulations under chronic dosing conditions
    Eric C Strain
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Drug Alcohol Depend 74:37-43. 2004
    ..This study compared the relative buprenorphine bioavailability of these different formulations...
  32. ncbi Experimentally-induced spontaneous opiate withdrawal: relationship to cigarette craving and expired air carbon monoxide
    Michelle R Lofwall
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Am J Addict 16:310-5. 2007
    ..Interestingly, craving was only reduced for items related to the positive reinforcing effects of smoking. These preliminary results suggest that OW may be a favorable context to initiate smoking cessation treatment interventions...
  33. ncbi Guidelines and methodological reviews concerning drug abuse liability assessment
    Robert L Balster
    Department of Pharmacology and Toxicology and Institute for Drug and Alcohol Studies, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298 0310, USA
    Drug Alcohol Depend 70:S13-40. 2003
    ..Thus, another goal of this review has been to identify areas where critical thinking and new guideline development are needed...
  34. ncbi QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial
    Erich F Wedam
    Division of Cardiology, Department of Medicine, Uniformed Services University of the Health Sciences, A3060, USUHS, Bethesda, MD 20814, USA
    Arch Intern Med 167:2469-75. 2007
    ..To compare the effects of 3 known hERG-associated channel blockers on the corrected QT (QTc), we conducted a randomized, controlled trial of opioid-addicted subjects...
  35. ncbi Comparing the physiological and subjective effects of self-administered vs yoked cocaine in humans
    Eric C Donny
    Department of Psychology, University of Pittsburgh, Pittsburgh, PA, USA
    Psychopharmacology (Berl) 186:544-52. 2006
    ..Studies with laboratory animals demonstrating different effects of self- vs experimenter-administered drug suggest that the ability to control or predict drug delivery may be an important determinant of drug action...
  36. ncbi Behavioral contingencies improve counseling attendance in an adaptive treatment model
    Robert K Brooner
    The Johns Hopkins University School of Medicine and Johns Hopkins Bayview Medical Center Baltimore, MD 21224, USA
    J Subst Abuse Treat 27:223-32. 2004
    ..001) and a lower rate of poor treatment response (46% vs. 79%, p < .001). The behavioral contingencies were well tolerated and strongly associated with excellent attendance across both lower and higher doses of weekly counseling...
  37. ncbi HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone
    David C Lott
    Chemical Dependency Program, Linden Oaks Hospital at Edward, 825 S West St, Naperville, IL 60540, USA
    J Subst Abuse Treat 31:187-94. 2006
    ..These results demonstrate that all three medications can be highly effective in decreasing HIV risk behaviors when the dose is optimized. Reductions in sexual behaviors for the METH group are consistent with known METH side effects...
  38. ncbi Voucher-based reinforcement of opiate abstinence during methadone detoxification
    Elias Robles
    Department of Pharmacology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Drug Alcohol Depend 65:179-89. 2002
    ..Voucher-based reinforcement procedures could be useful for successfully transitioning patients into opiate antagonist therapy, or drug-free treatments...

Research Grants15

  1. HUMAN BEHAVIORAL PHARMACOLOGY OF SUBSTANCE ABUSE
    George Bigelow; Fiscal Year: 2007
    ....
  2. PHARMACOLOGICAL MODULATION OF COCAINE EFFECTS
    George Bigelow; Fiscal Year: 2002
    ....
  3. HUMAN BEHAVIORAL PHARMACOLOGY OF DRUG ABUSE
    George Bigelow; Fiscal Year: 2002
    ..The cocaine dependence clinical trials will evaluate the efficacy of the serotonergic agents tryptophan and fluoxetine in the context of an incentive-based behavior therapy program. ..
  4. PHARMACOLOGICAL MODULATION OF COCAINE EFFECTS
    George Bigelow; Fiscal Year: 1993
    ..These studies are relevant to the treatment of intravenous drug abuse and to efforts to reduce the spread of AIDS and HIV infection by reducing HIV-associated risk behaviors...
  5. PHARMACOLOGICAL MODULATION OF COCAINE EFFECTS
    George Bigelow; Fiscal Year: 1991
    ....